Company / Capital Expenditures
TEVA PHARMACEUTICAL INDUSTRIES LTD Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$501.0M
FY2025
5-year range
$498.0M / $562.0M
FY2021-FY2025
Trend
+0.6%
vs FY2024
Sector context
#11 of 194
Health Care
What the data says
Among 194 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 6% for capital expenditures. Capital Expenditures returned to growth in FY2025 after 4 years of decline, reaching $501M.
Based on SEC 10-K filings.
$501M in FY2025 with a 5-year CAGR of -2.8%. Top quartile in the Health Care sector.
Declined from $526M to $501M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- -2.8%
- 10-Year CAGR
- -
Sector benchmark
+326.3% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.8%, indicating a declining trend.
- In FY2025, capital expenditures increased 0.6% year-over-year.
- Ranks #11 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $501.0M | +0.6% |
| FY2024 | $498.0M | -5.3% |
| FY2023 | $526.0M | -4.0% |
| FY2022 | $548.0M | -2.5% |
| FY2021 | $562.0M | -2.8% |
| FY2020 | $578.0M | +10.1% |
| FY2019 | $525.0M | -19.4% |
| FY2018 | $651.0M | -25.5% |
| FY2017 | $874.0M | -3.0% |
| FY2016 | $901.0M | +16.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026